Locations:
Search
Early results show patients experiencing deep and complete response
Inclusion of genomic profiling and risk factors recommended for treatment planning
Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer
Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Treatment assigned FDA review date in June 2025
Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit
Cleveland Clinic, the University of Minnesota and University of Cambridge receive $1M grant to develop point-of-care biosensor for early detection and treatment personalization
Long-acting antiemetics and high-dose steroids key to minimizing acute nausea
Greater awareness among young patients is needed
Neoadjuvant immunotherapy improves outcomes
Advertisement
Advertisement